AGIO
Price
$28.04
Change
-$0.18 (-0.64%)
Updated
May 8 closing price
Capitalization
1.62B
83 days until earnings call
DNLI
Price
$14.43
Change
+$0.11 (+0.77%)
Updated
May 8 closing price
Capitalization
2.08B
83 days until earnings call
Ad is loading...

AGIO vs DNLI

Header iconAGIO vs DNLI Comparison
Open Charts AGIO vs DNLIBanner chart's image
Agios Pharmaceuticals
Price$28.04
Change-$0.18 (-0.64%)
Volume$547.58K
Capitalization1.62B
Denali Therapeutics
Price$14.43
Change+$0.11 (+0.77%)
Volume$1.32M
Capitalization2.08B
AGIO vs DNLI Comparison Chart
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. DNLI commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a StrongBuy and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (AGIO: $28.04 vs. DNLI: $14.43)
Brand notoriety: AGIO and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 85% vs. DNLI: 89%
Market capitalization -- AGIO: $1.62B vs. DNLI: $2.08B
AGIO [@Biotechnology] is valued at $1.62B. DNLI’s [@Biotechnology] market capitalization is $2.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • AGIO’s TA Score: 5 bullish, 4 bearish.
  • DNLI’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, AGIO is a better buy in the short-term than DNLI.

Price Growth

AGIO (@Biotechnology) experienced а -9.37% price change this week, while DNLI (@Biotechnology) price change was -10.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

AGIO is expected to report earnings on Jul 31, 2025.

DNLI is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.08B) has a higher market cap than AGIO($1.62B). AGIO YTD gains are higher at: -14.668 vs. DNLI (-29.195). AGIO has higher annual earnings (EBITDA): -420.08M vs. DNLI (-492.89M). AGIO has more cash in the bank: 894M vs. DNLI (832M). DNLI has less debt than AGIO: DNLI (48.7M) vs AGIO (57M). AGIO has higher revenues than DNLI: AGIO (36.5M) vs DNLI (0).
AGIODNLIAGIO / DNLI
Capitalization1.62B2.08B78%
EBITDA-420.08M-492.89M85%
Gain YTD-14.668-29.19550%
P/E Ratio2.45N/A-
Revenue36.5M0-
Total Cash894M832M107%
Total Debt57M48.7M117%
FUNDAMENTALS RATINGS
AGIO vs DNLI: Fundamental Ratings
AGIO
DNLI
OUTLOOK RATING
1..100
1324
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1839
PRICE GROWTH RATING
1..100
6262
P/E GROWTH RATING
1..100
8798
SEASONALITY SCORE
1..100
2n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for DNLI (94). This means that AGIO’s stock grew somewhat faster than DNLI’s over the last 12 months.

AGIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that AGIO’s stock grew similarly to DNLI’s over the last 12 months.

AGIO's SMR Rating (18) in the Biotechnology industry is in the same range as DNLI (39). This means that AGIO’s stock grew similarly to DNLI’s over the last 12 months.

AGIO's Price Growth Rating (62) in the Biotechnology industry is in the same range as DNLI (62). This means that AGIO’s stock grew similarly to DNLI’s over the last 12 months.

AGIO's P/E Growth Rating (87) in the Biotechnology industry is in the same range as DNLI (98). This means that AGIO’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIODNLI
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 8 days ago
75%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 3 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
73%
View a ticker or compare two or three
Ad is loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FANIX43.34N/A
N/A
Fidelity Advisor Energy I
TGRIX13.20N/A
N/A
American Century International Gr I
TAREX23.41N/A
N/A
Third Avenue Real Estate Value Instl
ISCSX15.29N/A
N/A
VY® Columbia Contrarian Core S
APGZX104.46N/A
N/A
AB Large Cap Growth Z

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with INSM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then INSM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
-0.64%
INSM - AGIO
46%
Loosely correlated
-3.88%
AXON - AGIO
45%
Loosely correlated
+14.13%
OLMA - AGIO
45%
Loosely correlated
+0.86%
CRNX - AGIO
43%
Loosely correlated
+4.17%
RVMD - AGIO
42%
Loosely correlated
+11.29%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.77%
BEAM - DNLI
55%
Loosely correlated
+6.32%
ARWR - DNLI
55%
Loosely correlated
+1.45%
ACLX - DNLI
55%
Loosely correlated
+6.27%
RGNX - DNLI
54%
Loosely correlated
-1.24%
NRIX - DNLI
53%
Loosely correlated
+3.66%
More